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Oxidative stress has been implicated in schizophrenia where recent studies have demonstrated
decreased glutathione (GSH) levels in cerebrospinal fluid (52% depletion). Treatment with
2-cyclohexene-1-one (CHX) has been used previously to deplete glutathione in various animal models.
We observed that treatment of mice with CHX led to a dose-related decrease of GSH levels in the
frontal cortex and striatum. Reductions were 54% and 38%, respectively, with 120 mg/kg. The
current study aimed to investigate the behavioural effects of CHX?induced GSH depletion in
combination with dopaminergic hyperactivity induced by amphetamine treatment. This study also
aimed to assess if GSH depletion could be restored with N-acetyl cysteine (NAC) treatment. C57Bl/6
mice were treated with CHX (120 mg/kg, i.p.) and 60 mins later, NAC (300 or 1000 mg/kg i.p.) was
injected and assessment of locomotor activity began. One hour later, amphetamine (5 mg/kg i.p.) was
administered and behaviour assessed for another hour. Controls received saline injections. Total
glutathione levels were assessed using an enzymatic-recycling assay and locomotion was assessed
using video-tracking (Ethovision, Noldus). CHX-treated animals showed reduced locomotor activity as
well as decreased habituation. Amphetamine treatment caused similarly marked locomotor
hyperactivity in both saline and CHX-treated animals. NAC treatment reduced habituation but
otherwise did not influence baseline or amphetamine-induced locomotor activity. These results
suggest that, although CHX-induced GSH depletion in mice causes a reduction of baseline locomotor
activity, the locomotor hyperactivity caused by amphetamine treatment, an animal model of psychosis,
was not affected. NAC treatment did not reverse the behavioural effect of CHX or influence the action
of amphetamine. Biochemical analysis is underway to assess if NAC treatment ameliorates the effect
of CHX on GSH levels in the brain.
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